Genome-wide CRISPR Knockout Screen in LNCaP Cells Treated with Enzalutamide
To categorize gene loss events in enzalutamide-treated LNCaP cells, a genome-wide CRISPR knockout (KO) screen was performed. We quantified sgRNA abundance between initial and final timepoints in DMSO and enzalutamide treated cell populations Overall design: Comparative sgRNA abundance and enrichment analysis of CRISPR Screen data for LNCaP cells treated with Enzalutamide or DMSO (T0-DMSO, T0-EZ, TF-DMSO, TF-EZ)